Form 8-K - Current report:
SEC Accession No. 0001628280-17-011222
Filing Date
2017-11-08
Accepted
2017-11-08 17:09:38
Documents
3
Period of Report
2017-11-08
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K - Q3 2017 EARNINGS RELEASE q320178k-earningsrelease.htm 8-K 33767
2 EXHIBIT 99.1 - EARNINGS RELEASE Q3 2017 q32017-ex991earningsrelease.htm EX-99.1 271468
3 cumberlandpharmaimageaa02.jpg GRAPHIC 37721
  Complete submission text file 0001628280-17-011222.txt   358358
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 171187451
SIC: 2834 Pharmaceutical Preparations